CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| ANHL1931 | COG | A Randomized Phase 3 trial of Nivolumab(NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma | Pediatric CIRB | Available to Open |
| ACNS1221 | COG | A Phase II Study For The Treatment Of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years Of Age: A Groupwide Phase II Study | Pediatric CIRB | Completed |
| AALL06N1 | COG | A Study of Neurocognitive Function in Children Treated for ALL: A Group-wide; Non-Therapeutic Companion Study to AALL0232 | Pediatric CIRB | Completed |
| ACCL20N1CD | COG | Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States | Pediatric CIRB | Available to Open |
| PBTC-049 | PBTC | A Phase I study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma and CNS tumors harboring MET aberrations | Pediatric CIRB | Available to Open |
| ALTE21C1 | COG | Assessment of Clonal Hematopoiesis and its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors | Pediatric CIRB | Available to Open |
| ARST2031 | COG | A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS) | Pediatric CIRB | Available to Open |
| AREN03B2 | COG | Renal Tumors Classification; Biology; and Banking Study | Pediatric CIRB | Available to Open |
| ANBL0931 | COG | A Comprehensive Safety Trial of Chimeric Antibody 14.18 (ch14.18) with GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy | Pediatric CIRB | Completed |
| ADVL1416 | COG | A Phase 1 study of Ramucirumab; a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid tumors; including CNS Tumors | Pediatric CIRB | Available to Open |